MDACC Study No:2009-0226 ( NCT No: NCT00940381)
Title:A Phase I Trial of Sirolimus and Cetuximab in Patients with Advanced Malignancies
Principal Investigator:Filip Janku
Treatment Agent:Cetuximab; Sirolimus
Study Status:Terminated
Study Description:Unavailable
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:Cetuximab
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Weekly during cycle 1, at the end of cycle 2, and after second cycle every 1-2
cycles usually before the next cycle.
Home Care: Patients will be able to self-administer Sirolimus at home. The initial or
loading doses of Cetuximab will be given in the clinic. Subsequent doses may
be given at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Filip Janku
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-2632
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults